British biotechnology company Thalia Therapeutics has announced a significant milestone in its growth journey after securing €3.1 million (£2.75 million) in new funding while completing the acquisition of Sanmirna Therapeutics, a US clinical stage biotechnology company focused on microRNA therapies for cancer.
The combined funding and acquisition represent a major step forward for Thalia as it expands its RNA therapeutics pipeline and transitions from a preclinical business into a clinical stage biotechnology company.
The latest investment was backed by both new and existing investors, including Premier Miton, and will support the development of new RNA based medicines targeting cancer and cardiovascular disease.
A Major Step Towards Clinical Stage Development
Founded in 2014, Thalia Therapeutics has built its reputation around developing innovative RNA based therapeutics alongside advanced drug delivery technologies.
The company has focused its research on two major areas with significant unmet medical need:
- Oncology
- Cardiovascular disease
The acquisition of Sanmirna Therapeutics significantly strengthens this strategy by adding miRisten, a clinical stage therapeutic candidate designed to treat Acute Myeloid Leukaemia (AML).
Unlike Thalia’s existing preclinical pipeline, miRisten has already entered human clinical testing, allowing the company to accelerate its development timeline by several years.
Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, described the transaction as a transformational opportunity for the company.
He said the acquisition rapidly advances Thalia’s oncology programme while broadening its RNA therapeutics portfolio with an innovative clinical asset.
What is Sanmirna Therapeutics?
Sanmirna Therapeutics is a US biotechnology company founded by NLC Health Ventures.
The company specialises in developing therapies that target microRNA, a class of small RNA molecules that regulate gene expression and play important roles in many diseases, including cancer.
Its lead candidate, miRisten, has become the centrepiece of the acquisition.
The therapy was originally discovered at City of Hope, one of the world’s leading cancer research institutions, before progressing into clinical development.
Understanding miRisten
miRisten is designed to selectively inhibit microRNA 126 (miR 126).
Researchers believe this molecule plays a significant role in the development and progression of Acute Myeloid Leukaemia, an aggressive form of blood cancer.
By blocking microRNA 126, researchers hope to interrupt cancer cell survival mechanisms while reducing disease progression.
The treatment is currently undergoing a Phase 1 open label dose escalation clinical trial involving patients with relapsed or refractory AML.
Topline clinical results are expected during the first half of 2027.
Why Acute Myeloid Leukaemia Matters
Acute Myeloid Leukaemia is one of the most aggressive blood cancers.
The disease develops rapidly within the bone marrow, preventing healthy blood cell production.
According to Thalia Therapeutics:
- More than 22,000 new AML patients are diagnosed annually in the United States.
- Existing treatment options remain limited.
- Many patients experience relapse after initial treatment.
The company estimates today’s global AML treatment market is worth approximately US$3.9 billion, with forecasts suggesting it could grow to US$9.8 billion by 2035.
This creates both a significant medical opportunity and a large commercial market for successful new therapies.
Details of the Acquisition
Thalia Therapeutics will acquire the entire issued share capital of Sanmirna Therapeutics.
The agreement includes:
- Initial consideration of €4.2 million (£3.675 million)
- Deferred milestone payments worth up to €15 million (£13 million)
The milestone payments will depend on future clinical and commercial achievements as the programme progresses.
The acquisition immediately adds a clinical stage oncology asset to Thalia’s portfolio while introducing a new RNA therapeutic approach alongside the company’s existing RNA technologies.
How the €3.1 Million Funding Will Be Used
The newly raised capital will support several areas of development across Thalia’s pipeline.
Completing the miRisten Phase 1 Trial
Approximately €1.1 million has been allocated to complete the ongoing Phase 1 clinical study for miRisten.
The study is expected to conclude during the first half of 2027.
Advancing Cardiovascular Programmes
Around €869,000 will support Thalia’s bispecific cardiovascular RNA programmes as they move towards Investigational New Drug (IND) submission with the US Food and Drug Administration.
This represents another important milestone as the company expands beyond oncology.
Research, Operations and Growth
The remaining funding will provide working capital while supporting:
- Research and development
- Corporate operations
- Integration of Sanmirna Therapeutics
- Transaction related costs
Building a Diversified RNA Therapeutics Pipeline
One of Thalia’s strengths lies in the diversity of its research portfolio.
Rather than relying on a single therapeutic programme, the company is developing multiple RNA technologies targeting different diseases.
Its current portfolio now includes:
- Clinical stage oncology programmes
- Dual target small interfering RNA technology
- Cardiovascular RNA therapeutics
- Advanced delivery platforms
- Nuvec delivery technology
This diversified approach may reduce long term development risk while creating multiple commercial opportunities.
Growing Interest in RNA Medicines
RNA based therapies have become one of biotechnology’s fastest growing fields.
Following the success of RNA vaccines and advances in gene targeted medicines, investors continue backing companies developing next generation RNA treatments.
RNA therapeutics offer several potential advantages:
- Highly targeted treatment approaches
- Ability to regulate disease causing genes
- Potential applications across multiple diseases
- Faster drug discovery compared with some traditional approaches
Companies developing RNA medicines have attracted significant investment across Europe throughout 2026.
Part of a Growing UK BioTech Ecosystem
Thalia Therapeutics joins a growing list of UK biotechnology companies securing investment this year.
Recent examples include:
- STORM Therapeutics, which raised €47.5 million for RNA modifying cancer therapies.
- Engitix, which secured €21 million to advance oncology and fibrosis programmes.
- PlaqueTec, which raised €4.2 million to develop cardiovascular precision medicine.
- Ternary Therapeutics.
- Houdini Bio.
Together, these investments highlight increasing confidence in Britain’s biotechnology sector, particularly in RNA therapeutics, oncology, cardiovascular medicine and precision healthcare.
Across comparable European financing rounds announced during 2026, investment has exceeded €114 million, reflecting continued investor interest despite broader economic uncertainty.
Why the Acquisition Matters
The acquisition offers several strategic advantages for Thalia Therapeutics.
Faster Clinical Progress
Instead of relying solely on preclinical programmes, the company now owns a clinical stage asset already being tested in patients.
Broader Technology Portfolio
miRisten introduces microRNA inhibition as an additional therapeutic strategy alongside Thalia’s existing RNA technologies.
Greater Commercial Potential
Having multiple therapeutic programmes increases future licensing, partnership and commercialisation opportunities.
Stronger Investor Appeal
Clinical stage assets generally attract greater investor interest because they reduce some of the uncertainty associated with early stage drug development.
Leadership’s Vision
Dr David Solomon believes the acquisition creates substantial long term value for shareholders.
According to the company, Thalia now has three significant development assets progressing through different stages of clinical advancement.
These include:
- miRisten
- Nuvec
- A cardiovascular RNA programme
Each programme addresses large global healthcare markets worth billions of dollars annually.
This diversified portfolio provides several opportunities for future value creation as individual programmes advance through clinical development.
What Comes Next?
Over the next 18 months, several important milestones are expected.
Investors and industry observers will be watching for:
- Completion of miRisten’s Phase 1 clinical trial
- Topline clinical data in H1 2027
- Progress towards FDA IND submission for cardiovascular assets
- Integration of Sanmirna Therapeutics
- Expansion of Thalia’s broader RNA therapeutics platform
Positive clinical results could significantly strengthen the company’s position within the rapidly growing RNA therapeutics sector.
The Bigger Picture
RNA medicines are reshaping modern biotechnology.
While much public attention initially focused on RNA vaccines, researchers are increasingly applying RNA technologies to cancer, cardiovascular disease, rare diseases and genetic disorders.
Thalia Therapeutics represents part of this next generation of biotechnology companies seeking to translate RNA science into new treatments for patients with limited therapeutic options.
The combination of fresh investment, a strengthened clinical pipeline and a strategic acquisition places the company in a stronger position as competition intensifies across the RNA therapeutics landscape.
Frequently Asked Questions
What is Thalia Therapeutics?
Thalia Therapeutics is a UK biotechnology company developing RNA based therapeutics and drug delivery technologies for oncology and cardiovascular disease.
How much funding has Thalia Therapeutics raised?
The company has announced a €3.1 million (£2.75 million) funding round supported by new and existing investors, including Premier Miton.
What is Sanmirna Therapeutics?
Sanmirna Therapeutics is a US clinical stage biotechnology company developing microRNA targeted therapies for cancer.
What is miRisten?
miRisten is an investigational RNA therapy designed to inhibit microRNA 126 for the treatment of Acute Myeloid Leukaemia.
What stage is miRisten currently in?
The therapy is currently being evaluated in a Phase 1 clinical trial involving patients with relapsed or refractory Acute Myeloid Leukaemia.
Why is the acquisition important?
The acquisition immediately transforms Thalia into a clinical stage biotechnology company while significantly accelerating its oncology pipeline.
Final Thoughts
Thalia Therapeutics’ €3.1 million funding round and acquisition of Sanmirna Therapeutics mark a significant milestone for the British biotechnology company.
By adding a clinical stage oncology programme to its existing RNA platform, Thalia is accelerating its transition into a more mature biotechnology business with multiple development programmes across cancer and cardiovascular disease.
As RNA therapeutics continue to attract investment and reshape modern medicine, Thalia’s strengthened pipeline positions the company to play an increasingly important role in the future of precision healthcare.
Also Read: Sprinklr vs Talkwalker (by Hootsuite) – Deep ORM Comparison (2026)